Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002258 · ClinicalTrials.gov registry record · Phase 1
A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia
A Phase 1 study, sponsored by Sandoz.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002258: Completed Phase 1 study, sponsored by Sandoz.
NCT00002258 is a Phase 1 study that has completed, run by Sandoz. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002258, a Phase 1 study, has completed, sponsored by Sandoz.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
To determine the safety, tolerability and maximum tolerated dose of SDZ ILE 964 administered by daily subcutaneous injections in patients infected with human immunodeficiency virus (HIV) who have cytopenias (low blood cell counts). To obtain information about the biologic effects of SDZ ILE 964 administration in improving blood counts in HIV-infected patients. To obtain information about the effects of SDZ ILE-964 administration on both parameters of HIV replication and on residual immunologic function.
Interventions
- DRUG Interleukin-3
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
What the finished NCT00002258 record still lists
NCT00002258 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Interleukin-3 is the first listed.
NCT00002258 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002258 about?
NCT00002258 is a clinical study titled "A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia". To determine the safety, tolerability and maximum tolerated dose of SDZ ILE 964 administered by daily subcutaneous injections in patients infected with human immunodeficiency virus (HIV) who have cytopenias (low blood cell counts). To obtain information about the biologic effects of SDZ ILE 964 admi...
What is the current status of trial NCT00002258?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00002258?
The interventions under investigation include: Interleukin-3 (DRUG).
Who is sponsoring clinical trial NCT00002258?
This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.